Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01777256
Recruitment Status : Terminated (This study met a protocol defined futility criterion and will be terminated following completion of the Follow Up Visit on the last subject randomised.)
First Posted : January 28, 2013
Last Update Posted : April 26, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Terminated
Actual Primary Completion Date : March 1, 2014
Actual Study Completion Date : March 31, 2014
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 July 19, 2017
February 16, 2018